Zydus Cadila seeks an emergency use approval for three-dose vaccine that is needle-free

Zydus Cadila stated on Thursday that it has applied to the office of the Drug Controller General of India (DCGI) for an Emergency Use Authorization (EUA) for ZyCoV-D, its Plasmid DNA Vaccine against Covid-19. In India, the business conducted the largest clinical trial for its Covid-19 vaccine, with over 50 locations participating. This was also the first time any Covid-19 vaccination had been studied in an Indian adolescent population aged 12 to 18. In this age group, almost 1,000 people were enrolled, and the vaccine was shown to be safe and well tolerated. To know more, watch the full video!

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting